Tags: parkinsons | disease | abbvie | tavapadon | drug | motor function

Study: Parkinson's Disease Drug Improves Symptoms

man holding hand to stop from shaking while picking up glass of water
(Dreamstime)

Monday, 09 December 2024 10:58 AM EST

AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.

The drug, tavapadon, helped significantly improve motor functions, including eating and walking, the company said.

The majority of side-effects reported were mild to moderate in severity, it said.

AbbVie plans to submit a marketing application to the U.S. Food & Drug Administration next year.

© 2025 Thomson/Reuters. All rights reserved.


Health-News
AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study. The drug, tavapadon, helped significantly improve motor functions, including eating and walking, the company said. The majority of side-effects reported were mild...
parkinsons, disease, abbvie, tavapadon, drug, motor function
63
2024-58-09
Monday, 09 December 2024 10:58 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Newsmax2 Live
 
On Now:1:30p ET • Conversations With Nancy Brinker
Coming Up:2:00p ET • The Record With Greta Van Susteren Weekly
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© 2025 Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved